Linked Life Data

21765917

Source:http://linkedlifedata.com/resource/pubmed/id/21765917

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-7-18
pubmed:abstractText
Galectin-3 is a human lectin involved in many cellular processes including differentiation, apoptosis, angiogenesis, neoplastic transformation, and metastasis. We evaluated galectin-3C, an N-terminally truncated form of galectin-3 that is thought to act as a dominant negative inhibitor, as a potential treatment for multiple myeloma (MM). Galectin-3 was expressed at varying levels by all 9 human MM cell lines tested. In vitro galectin-3C exhibited modest anti-proliferative effects on MM cells and inhibited chemotaxis and invasion of U266 MM cells induced by stromal cell-derived factor (SDF)-1?. Galectin-3C facilitated the anticancer activity of bortezomib, a proteasome inhibitor approved by the FDA for MM treatment. Galectin-3C and bortezomib also synergistically inhibited MM-induced angiogenesis activity in vitro. Delivery of galectin-3C intravenously via an osmotic pump in a subcutaneous U266 cell NOD/SCID mouse model of MM significantly inhibited tumor growth. The average tumor volume of bortezomib-treated animals was 19.6% and of galectin-3C treated animals was 13.5% of the average volume of the untreated controls at day 35. The maximal effect was obtained with the combination of galectin-3C with bortezomib that afforded a reduction of 94% in the mean tumor volume compared to the untreated controls at day 35. In conclusion, this is the first study to show that inhibition of galectin-3 is efficacious in a murine model of human MM. Our results demonstrated that galectin-3C alone was efficacious in a xenograft mouse model of human MM, and that it enhanced the anti-tumor activity of bortezomib in vitro and in vivo. These data provide the rationale for continued testing of galectin-3C towards initiation of clinical trials for treatment of MM.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1932-6203
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e21811
pubmed:meshHeading
pubmed-meshheading:21765917-Animals, pubmed-meshheading:21765917-Antineoplastic Agents, pubmed-meshheading:21765917-Boronic Acids, pubmed-meshheading:21765917-Cell Line, Tumor, pubmed-meshheading:21765917-Cell Proliferation, pubmed-meshheading:21765917-Cell Survival, pubmed-meshheading:21765917-Chemotaxis, pubmed-meshheading:21765917-Dependovirus, pubmed-meshheading:21765917-Drug Synergism, pubmed-meshheading:21765917-Endothelial Cells, pubmed-meshheading:21765917-Fibroblast Growth Factor 2, pubmed-meshheading:21765917-Galectin 3, pubmed-meshheading:21765917-Green Fluorescent Proteins, pubmed-meshheading:21765917-Humans, pubmed-meshheading:21765917-Immunoglobulin E, pubmed-meshheading:21765917-Immunoglobulin lambda-Chains, pubmed-meshheading:21765917-Integrin alphaVbeta3, pubmed-meshheading:21765917-Mice, pubmed-meshheading:21765917-Multiple Myeloma, pubmed-meshheading:21765917-Neoplasm Invasiveness, pubmed-meshheading:21765917-Neovascularization, Pathologic, pubmed-meshheading:21765917-Pyrazines, pubmed-meshheading:21765917-Umbilical Veins, pubmed-meshheading:21765917-Vascular Endothelial Growth Factor A, pubmed-meshheading:21765917-Xenograft Model Antitumor Assays
pubmed:year
2011
pubmed:articleTitle
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
pubmed:affiliation
Division of Hematology & Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, Texas, United States of America.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural